Feb 14, 2024, 13:40
Karen Bedirian: Happy to share that IMMONC received regulatory approval to conduct a trial of BAL+BOT among patients with metastatic non-small cell lung cancer
Karen Bedirian, Projects Director at Immune Oncology Research Institute, shared on LinkedIn:
“Happy to share that IMMONC received regulatory approval to conduct a clinical trial of BAL+BOT among patients with metastatic non-small cell lung cancer.
We received the approval of the Center of Drug and Medical Technology in just 30 working days and the approval of the MoH Ethics Committee in just 9 working days.
Grateful for the team’s efforts. Immune Oncology Research Institute
Thank you Agenus for the continued support.”
Source: Karen Bedirian/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 09:39
Nov 13, 2024, 08:59